United StatesHealthcare and life sciences2022 – ongoingThermo Fisher Scientific
Machine learning for PPD clinical-trial site selection
Thermo Fisher's PPD business deployed machine learning to support clinical-trial site selection
Problem
Clinical-trial teams needed to choose suitable research sites and assess how studies were performing. Site-level information was held across PPD and Medidata.
Approach
PPD used machine-learning analysis drawing on its site-level data and Medidata's data. Thermo Fisher's clinical-research executive confirmed deployment for site selection and described better visibility into trial performance.
Results
No published figures
Takeaway
The reported benefit concerned decisions about trial sites. Thermo Fisher did not disclose an improvement in recruitment speed or trial costs.
Categories
- Size
- Large enterprise
- Industry
- Healthcare and life sciences
- Business function
- IT and R&DProduction and quality
- Innovation type
- Process innovation
- AI technology
- Predictive analytics and ML
- Adoption
- Vendor solution
- Evidence
- Vendor case study
Sources
Source summaries
Medidata included a Thermo Fisher executive's confirmation that PPD had deployed machine-learning analysis for site selection. The executive also described greater visibility into trial performance, without quantifying the results.
Full details are in the original sources.